Pharmaceuticals(IN00372.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Pharmaceuticals
IN00372.US
News
View More

Novo Nordisk Stock Dips As Company Faces GLP-1 Antitrust Lawsuit

Novo Nordisk A/S (NYSE:NVO) shares fell 3.40% to $56.91 after the company faced a lawsuit from Strive Specialties. The lawsuit alleges that Novo and Eli Lilly illegally blocked access to customized, lower-cost versions of their GLP-1 weight-loss drugs, claiming they used market dominance to prevent patients from obtaining compounded alternatives. Strive seeks monetary damages and a court order against the exclusivity agreements. Novo Nordisk stated that the claims are without merit and they will defend themselves vigorously in court.

fidelity·
US
NVO
-3.35%
fidelity·
US
NVO
-3.35%

U.S. stock market midday update: Gelteq falls nearly 10%, trading volume surges, market sentiment fluctuations attract attention

Gelteq fell 9.91%; Eli Lilly fell 3.63%, with a transaction volume of USD 3.2 billion; Novo Nordisk fell 3.34%, with a transaction volume of USD 1.112 billion; Johnson & Johnson rose 0.38%, with a transaction volume of USD 943 million; AstraZeneca fell 2.07%, with a market value of USD 292.7 billion

Tracking Unusual Activity·
US
GELS
+8.62%
Tracking Unusual Activity·
US
GELS
+8.62%

This pharma stock just got whacked — there's still a major catalyst ahead

Eli Lilly's stock fell 5% after the FDA extended review deadlines for its diabetes drug, orforglipron. Despite this setback, analysts believe FDA approval is likely by April 10, which could serve as a significant catalyst for the stock. Meanwhile, Costco is gaining positive sentiment after strong December sales, with Bernstein calling it undervalued and projecting further growth. The market is also buoyed by strong performances from semiconductor stocks and financials, with Goldman Sachs and BlackRock reporting better-than-expected earnings. Overall, the market remains in overbought territory, prompting some cash trimming in positions.

CNBC·
US
LLY
-3.88%
US
COST
+0.62%
CNBC·
US
LLY
-3.88%
US
COST
+0.62%

Atea Pharmaceuticals Unveils Antiviral Pipeline Progress and Phase 3 HCV Trial Updates

Atea Pharmaceuticals Inc. presented updates on its antiviral pipeline at the J.P. Morgan Healthcare Conference, focusing on its combination therapy for hepatitis C. The Phase 3 C-BEYOND trial has completed enrollment, with results expected in mid-2026. The C-FORWARD trial is also on track for full enrollment by mid-2026, with results by year-end 2026. The company reported $301.8 million in cash and investments as of December 31, 2025, and plans to start a Phase 1 trial for hepatitis E in mid-2026. Market insights indicate a demand for simpler HCV treatment regimens.

Reuters·
US
AVIR
-2.12%
Reuters·
US
AVIR
-2.12%

Lilly, Novo sued over GLP‑1 drug dominance by compounding pharmacy

Eli Lilly and Novo Nordisk are facing a lawsuit from Strive Specialties, a compounding pharmacy, in Texas. The lawsuit alleges that the drugmakers are blocking access to customized versions of their popular GLP-1 weight-loss medications, such as Ozempic and Mounjaro, by striking exclusive deals with telehealth providers. Strive claims this prevents doctors from prescribing tailored doses. Both companies have denied the allegations, with Lilly stating the lawsuit is an attempt to distract from Strive's own conduct. Strive seeks monetary damages and a court order against the exclusivity agreements.

Reuters·
US
LLY
-3.88%
US
NVO
-3.35%
Reuters·
US
LLY
-3.88%
US
NVO
-3.35%
Posts
View More

Added some $Novo Nordisk AS(NVO.US) in the night session

I've been feeling the position was too small these days, so I topped up this time. Now just be patient and let time do its work!

 

Not investment ...

The recent biotech stock market is really a tale of two extremes. CRSP and NTLA in hand are still struggling, chasing the dream of gene editing but completely missing the big surge of MLTX and ELVN, w...

$Novo Nordisk AS(NVO.US) If you saw this message and bought on the 23rd, it has now rebounded to around 60. The power of NVO's weight-loss drug should be more optimistic in the long term. Those with h...

$Novo Nordisk AS(NVO.US) The position is a bit small, but it's okay as long as there's profit😂

$Tilray Brands(TLRY.US)Investment Theme, Trump Defense News Sentiment.

© 2026 Longbridge｜Disclaimer